Nuvectis Pharma (NASDAQ:NVCT) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Nuvectis Pharma (NASDAQ:NVCT) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research firms have also weighed in on NVCT. Weiss Ratings raised Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research report on Thursday, September 24th. Loop Capital set a $40.00 target price on Nuvectis Pharma in a research note on Tuesday, September 1st. Cantor Fitzgerald started coverage on shares of Nuvectis Pharma in a report on Monday, August 24th. They issued an “overweight” rating for the company. Finally, Lucid Cap Mkts upgraded shares of Nuvectis Pharma to a “strong-buy” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.25.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $20.91 on Friday. The stock’s fifty day moving average price is $20.89 and its two-hundred day moving average price is $14.88. The company has a market cap of $719.09 million, a PE ratio of -11.06 and a beta of -0.21. Nuvectis Pharma has a fifty-two week low of $5.55 and a fifty-two week high of $29.27.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.78). On average, equities analysts predict that Nuvectis Pharma will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Nuvectis Pharma in the 2nd quarter worth about $18,414,000. Alyeska Investment Group L.P. bought a new position in Nuvectis Pharma in the second quarter valued at about $5,057,000. Stonepine Capital Management LLC bought a new position in Nuvectis Pharma in the second quarter valued at about $735,600. Bank of New York Mellon Corp acquired a new stake in shares of Nuvectis Pharma during the second quarter valued at about $676,000. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Nuvectis Pharma by 17.3% during the third quarter. Oppenheimer & Co. Inc. now owns 86,291 shares of the company’s stock valued at $1,822,000 after purchasing an additional 12,725 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors.

Key Nuvectis Pharma News

Here are the key news stories impacting Nuvectis Pharma this week:

• Neutral Sentiment: HC Wainwright maintained its Buy rating and $39 price target, well above the reported $20.91 share price. However, the firm also lowered its earnings estimates. Nuvectis Pharma analyst estimates
• Negative Sentiment: Zacks Research downgraded Nuvectis from Hold to Strong Sell, a notably more bearish view that could weigh on investor sentiment. TickerReport article
• Negative Sentiment: HC Wainwright cut its projected losses for Q4 2026 and FY2026–FY2028, including lowering FY2028 EPS expectations from ($1.24) to ($2.35). The deeper projected losses may add concern about the company’s path to profitability, despite the firm’s Buy rating. Nuvectis Pharma analyst estimates

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.